Cancer Drug Developer “Biosight” Lists on Nasdaq
Biosight has merged with US immunotherapy company Advaxis at a company valuation of $280 million and will trade under the BSTX sticker. The company’s investors (Arkin Holdings, Israel Biotechnology Fund…
Continue Reading
Cancer Drug Developer “Biosight” Lists on Nasdaq